 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 12» |
- || zanzalintinib (XL092) / Exelixis
New P1 trial: Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer (clinicaltrials.gov) - Jan 28, 2025
P1, N=36, Not yet recruiting, Sponsor: Washington University School of Medicine
- zanzalintinib (XL092) / Exelixis
PRO-XL: A phase II study of zanzalintinib (XL092) in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on lutetium-177 (177Lu)-PSMA-617. (Level 1, West Hall; Poster Bd #: M4) - Jan 7, 2025 - Abstract #ASCOGU2025ASCO_GU_577;
P2
Clinical Trial Registration Number: NCT06568562 The abstract will be released to the public on February 10, 2025 at 2:00 PM PST
- ||| zanzalintinib (XL092) / Exelixis
Trial completion date: STELLAR-305: Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Dec 27, 2024
P2/3, N=600, Recruiting, Sponsor: Exelixis
Clinical Trial Registration Number: NCT06568562 The abstract will be released to the public on February 10, 2025 at 2:00 PM PST Trial completion date: Mar 2028 --> Mar 2029
- ||| Enrollment change: Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - Dec 26, 2024
P1/2, N=314, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Mar 2028 --> Mar 2029 N=675 --> 314
- zanzalintinib (XL092) / Exelixis
Zanzalintinib (XL092) alone or in combination with atezolizumab in patients (pts) with refractory metastatic colorectal cancer (mCRC): Results from an expansion cohort of the phase 1 STELLAR-001 study. (Level 1, West Hall; Poster Bd #: E13) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_797;
P1
Clinical Trial Registration Number: NCT03845166. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- || zanzalintinib (XL092) / Exelixis
Trial completion date, Trial primary completion date, Combination therapy, Metastases: STELLAR-001: A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (clinicaltrials.gov) - Nov 18, 2024
P1, N=325, Active, not recruiting, Sponsor: Exelixis
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC Trial completion date: Nov 2024 --> May 2027 | Trial primary completion date: Nov 2024 --> Aug 2026
- | zanzalintinib (XL092) / Exelixis
Enrollment open, Metastases: XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma (clinicaltrials.gov) - Oct 30, 2024
P2, N=29, Recruiting, Sponsor: Northwestern University
Trial completion date: Nov 2024 --> May 2027 | Trial primary completion date: Nov 2024 --> Aug 2026 Not yet recruiting --> Recruiting
- ||| zanzalintinib (XL092) / Exelixis
Enrollment closed, Enrollment change: Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) (clinicaltrials.gov) - Sep 19, 2024
P1/2, N=25, Active, not recruiting, Sponsor: Exelixis
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=140 --> 25
- Cabometyx (cabozantinib tablet) / Exelixis, zanzalintinib (XL092) / Exelixis
Investigation of cabozantinib and zanzalintinib differentiation via in vitro kinase profiling and in vivo tissue and tumor distribution (Exhibition Hall) - Sep 7, 2024 - Abstract #EORTCNCIAACR2024EORTC_NCI_AACR_198;
Unless they are part of the media programme, embargoed or not consented, all abstracts will be released on 9 October 2024. All other abstracts will be released on the day of presentation.
- | zanzalintinib (XL092) / Exelixis
New P2 trial, Metastases: XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma (clinicaltrials.gov) - Aug 26, 2024
P2, N=29, Not yet recruiting, Sponsor: Northwestern University
- || zanzalintinib (XL092) / Exelixis
New P2 trial, Metastases: PRO-XL: XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Aug 23, 2024
P2, N=32, Not yet recruiting, Sponsor: University of Utah
- ||| Tecentriq (atezolizumab) / Roche, zanzalintinib (XL092) / Exelixis
P3 data, Journal, Metastases: STELLAR-303: randomized phase III study of zanzalintinib (Pubmed Central) - Jul 23, 2024
P3
Presented is the design of STELLAR-303, a global, phase III, open-label, randomized study evaluating zanzalintinib plus atezolizumab versus regorafenib in patients with non-MSI-H mCRC who progressed during/after or are refractory/intolerant to standard-of-care therapy. The primary end point is overall survival in patients without liver metastases.Clinical Trial Registration: NCT05425940 (ClinicalTrials.gov).
- ||||| zanzalintinib (XL092) / Exelixis
Trial initiation date: STELLAR-305: Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 18, 2024
P2/3, N=500, Recruiting, Sponsor: Exelixis
The primary end point is overall survival in patients without liver metastases.Clinical Trial Registration: NCT05425940 (ClinicalTrials.gov). Initiation date: Nov 2023 --> Jun 2024
- ||||| zanzalintinib (XL092) / Exelixis
Enrollment closed, Metastases: STELLAR-303: Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 4, 2024
P3, N=874, Active, not recruiting, Sponsor: Exelixis
Initiation date: Nov 2023 --> Jun 2024 Recruiting --> Active, not recruiting
- ||| Enrollment closed, Trial completion date, Trial primary completion date: Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - Jun 3, 2024
P1/2, N=675, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2026 --> Sep 2025 | Recruiting --> Active, not recruiting | Trial completion date: Sep 2027 --> Nov 2026
- Keytruda (pembrolizumab) / Merck (MSD), zanzalintinib (XL092) / Exelixis
STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma. (Hall A; Poster Bd #: 429b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3564;
P2/3
If minimum efficacy requirements are met in phase 2, the study will proceed to phase 3 with approximately 500 patients enrolled across both phases. STELLAR-305 is currently enrolling, with 200 sites estimated for global expansion.
- Stivarga (regorafenib) / Bayer, Tecentriq (atezolizumab) / Roche, zanzalintinib (XL092) / Exelixis
STELLAR-303: A randomized phase 3 study of zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated metastatic colorectal cancer. (Hall A; Poster Bd #: 295a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2698;
P3
Safety will also be assessed. STELLAR-303 enrollment is ongoing in the US, Europe, and Asia-Pacific region.
- Opdivo (nivolumab) / BMS, zanzalintinib (XL092) / Exelixis
Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study. (Hall A; Poster Bd #: 304a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1776;
P3
The secondary endpoint is OS; safety will also be assessed. STELLAR-304 is currently recruiting patients in Europe, North and South America, and the Asia-Pacific region.
- zanzalintinib (XL092) / Exelixis
Biomarker analysis of zanzalintinib in clear cell renal cell carcinoma from STELLAR-001. (Hall A; Poster Bd #: 240) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1711;
P1
The reduction in immunosuppressive immune cells and activation of effector immune cells by zanza support the rationale for combining zanza with immune checkpoint inhibitors. Given the small sample sizes, further investigation in larger studies is warranted.
- || zanzalintinib (XL092) / Exelixis
Trial primary completion date, Combination therapy, Metastases: STELLAR-001: A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (clinicaltrials.gov) - Feb 19, 2024
P1, N=325, Active, not recruiting, Sponsor: Exelixis
Given the small sample sizes, further investigation in larger studies is warranted. Trial primary completion date: Nov 2023 --> Nov 2024
- ||| Enrollment change, Trial completion date, Trial primary completion date: Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - Feb 15, 2024
P1/2, N=675, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Nov 2023 --> Nov 2024 N=470 --> 675 | Trial completion date: Nov 2026 --> Sep 2027 | Trial primary completion date: Aug 2025 --> Jun 2026
- || zanzalintinib (XL092) / Exelixis
PK/PD data, Preclinical, Journal: A simple and sensitive liquid chromatography triple quadrupole mass spectrometry method for the determination of XL092 in monkey plasma and its application to pharmacokinetic study. (Pubmed Central) - Jan 31, 2024
The validated method was demonstrated to be selective, sensitive, and reliable, and has been successfully applied to the pharmacokinetic study of XL092 in monkey plasma. XL092 showed moderate short half-life (~3.81?h) and good oral bioavailability (80%).
- Keytruda (pembrolizumab) / Merck (MSD), zanzalintinib (XL092) / Exelixis
Zanzalintinib Plus Pembrolizumab Versus Pembrolizumab Alone In Patients With PD-L1 Positive Metastatic Head And Neck Squamous Cell Carcinoma (STELLAR-305): A Double-Blind, Randomized, Placebo-Controlled, Phase 2/3 Study (JW Marriott Desert Ridge Grand Canyon 6-8; Poster Screen #3) - Jan 24, 2024 - Abstract #MHNCS2024MHNCS_190;
P2/3
While pembrolizumab monotherapy results in low response rates, the addition of 5FU/cisplatin adds significant toxicity for pts... TBD
- ||||| zanzalintinib (XL092) / Exelixis
Enrollment change, Metastases: STELLAR-303: Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 22, 2024
P3, N=874, Recruiting, Sponsor: Exelixis
TBD N=600 --> 874
- |||| zanzalintinib (XL092) / Exelixis
New P1/2 trial: Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) (clinicaltrials.gov) - Jan 5, 2024
P1/2, N=140, Recruiting, Sponsor: Exelixis
- |||||| zanzalintinib (XL092) / Exelixis
Enrollment open, Trial completion date: STELLAR-305: Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Dec 20, 2023
P2/3, N=500, Recruiting, Sponsor: Exelixis
N=600 --> 874 Not yet recruiting --> Recruiting | Trial completion date: Dec 2027 --> Mar 2028
- Stivarga (regorafenib) / Bayer, Tecentriq (atezolizumab) / Roche, zanzalintinib (XL092) / Exelixis
Zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated MSS/MSI-low metastatic colorectal cancer (mCRC): The randomized phase 3 STELLAR-303 study. (Level 1, West Hall; Poster Bd # N17) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_642;
P3
Not yet recruiting --> Recruiting | Trial completion date: Dec 2027 --> Mar 2028 Most recently, in the phase 3 LEAP-017 study of patients with non
- || zanzalintinib (XL092) / Exelixis
Enrollment closed, Enrollment change, Combination therapy, Metastases: STELLAR-001: A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (clinicaltrials.gov) - Nov 8, 2023
P1, N=325, Active, not recruiting, Sponsor: Exelixis
Most recently, in the phase 3 LEAP-017 study of patients with non Recruiting --> Active, not recruiting | N=921 --> 325
- |||||||||| zanzalintinib (XL092) / Exelixis
New P2/3 trial: STELLAR-305: Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Oct 13, 2023
P2/3, N=500, Not yet recruiting, Sponsor: Exelixis
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, zanzalintinib (XL092) / Exelixis
Preliminary results of a prospective pilot study using CD8 ImmunoPET imaging to evaluate the immune response to radiation therapy (ELIXR) (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1058;
P1
Concurrent therapies included cabozantinib, nivolumab, and an experimental chemotherapy XL092 (table 1)...Conclusions Increase in intratumoral CD8+ T cell activity was observed during RT in mRCC and lymphoma patients. Follow-up may reveal the prognostic implications of visualizing the immunogenic effects of radiation using CD8 ImmunoPET.
- || Trial completion date, Trial primary completion date: Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - Aug 15, 2023
P1/2, N=470, Recruiting, Sponsor: Hoffmann-La Roche
Follow-up may reveal the prognostic implications of visualizing the immunogenic effects of radiation using CD8 ImmunoPET. Trial completion date: Aug 2025 --> Nov 2026 | Trial primary completion date: Apr 2024 --> Aug 2025
- Opdivo (nivolumab) / Ono Pharma, BMS, zanzalintinib (XL092) / Exelixis
STELLAR-304: A randomized phase III study of zanzalintinib (XL092) and nivolumab in non-clear cell renal cell carcinoma (nccRCC) () - Jul 27, 2023 - Abstract #ESMO2023ESMO_3366;
P3
The secondary endpoint is OS; safety will also be assessed. STELLAR-304 is currently recruiting patients in 29 countries in Europe, North and South America, and the Asia-Pacific region.
- zanzalintinib (XL092) / Exelixis
Zanzalintinib in combination with immune checkpoint inhibitors: Design of the renal cell carcinoma expansion stage cohorts in STELLAR-002 (Live; Virtual) - Jun 16, 2023 - Abstract #KCRS2023KCRS_35;
- Tecentriq (atezolizumab) / Roche, zanzalintinib (XL092) / Exelixis
Zanzalintinib (XL092) in combination with atezolizumab for previously treated metastatic colorectal cancer (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_280;
P3
STELLAR-304 is currently recruiting patients in 29 countries in Europe, North and South America, and the Asia-Pacific region. Immune checkpoint inhibitor (ICI) therapy with nivolumab
- |||| Tecentriq (atezolizumab) / Roche, zanzalintinib (XL092) / Exelixis
In Sydney, Australia 🇦🇺 to launch STELLAR 303 in Asia & Pacific countries. Testing XL-092+Atezolizumab in chemo refractory MSS #crcsm. Multiple endpoints to tackle including RAS wild type & site of metastasis 💫 @OncoAlert @ExelixisInc https://t.co/9HVFYIhzH4 (Twitter) - Apr 30, 2023
- Stivarga (regorafenib) / Bayer, Tecentriq (atezolizumab) / Roche, zanzalintinib (XL092) / Exelixis
STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer. (On Demand | Hall A; Poster Bd # 327a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3148;
P3
Regorafenib and trifluridine-tipiracil are approved in third- or later-line setting, but survival benefit is limited. Immune checkpoint inhibitor (ICI) therapy with nivolumab
- ||| Stivarga (regorafenib) / Bayer, Tecentriq (atezolizumab) / Roche, zanzalintinib (XL092) / Exelixis
XL092 Plus Atezolizumab Vs Regorafenib Under Investigation in MSS/MSI-Low mCRC @dgsomucla @ASCO #crcsm #GI23 https://t.co/9rCh1dM1gE (Twitter) - Feb 7, 2023
- ||||| zanzalintinib (XL092) / Exelixis
At #GI23 we had the pleasure of speaking with @AnwaarSaeed3 of @UPMCHillmanCC who gave us an overview of the STELLAR-303 trial evaluating XL092 in pretreated, MMS/MSI-low #ColorectalCancer More on https://t.co/ys1d8pDAKO @ASCO #GI23 #GIsm #GastrointestinalCancer #CRC #CRCsm (Twitter) - Jan 21, 2023
- || zanzalintinib (XL092) / Exelixis
Enrollment change: STELLAR-002: Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (clinicaltrials.gov) - Jan 20, 2023
P1, N=1078, Recruiting, Sponsor: Exelixis
Immune checkpoint inhibitor (ICI) therapy with nivolumab N=622 --> 1078
- |||||| zanzalintinib (XL092) / Exelixis
Enrollment open: STELLAR-304: Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Jan 18, 2023
P3, N=291, Recruiting, Sponsor: Exelixis
N=622 --> 1078 Not yet recruiting --> Recruiting
- |||||||||| zanzalintinib (XL092) / Exelixis
New P3 trial: STELLAR-304: Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Jan 10, 2023
P3, N=291, Not yet recruiting, Sponsor: Exelixis
- MODULE 2: Optimizing the Use of Immune Checkpoint Inhibitors in the Management of mCRC (San Francisco Marriott Marquis, Golden Gate Ballroom, Salon A (B2 Level)) - Dec 23, 2022 - Abstract #ASCOGI2023ASCO_GI_997;
This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Exelixis Inc, Lilly, Natera Inc, and Seagen Inc. Key data informing the rational incorporation of pembrolizumab, nivolumab and nivolumab/ipilimumab for microsatellite instability-high/mismatch repair-deficient mCRC Early results with and ongoing investigation of immune checkpoint inhibitors in combination with other systemic approaches (eg, chemotherapy, targeted therapy) for MSI-H/dMMR advanced CRC Biologic rationale for the investigation of immune checkpoint inhibition for microsatellite-stable (MSS) mCRC Clinical activity and safety observed with cabozantinib in combination with anti-PD-1/PD-L1 antibodies among patients with MSS mCRC in early-phase trials (eg, COSMIC-021 cohort 16, CAMILLA cohort 2) Pharmacologic and pharmacodynamic comparison of cabozantinib and XL092 Design, eligibility and efficacy and safety endpoints for the Phase III STELLAR-303 trial comparing XL092/atezolizumab to regorafenib for relapsed/refractory (R/R) MSS mCRC Available data with and ongoing investigation of other immune checkpoint inhibitor-based strategies (eg, lenvatinib/pembrolizumab, regorafenib/pembrolizumab) for MSS mCRC Available data with and ongoing investigation of other immune checkpoint inhibitor-based strategies (eg, lenvatinib/pembrolizumab, regorafenib/pembrolizumab) for patients with MSS mCRC
- Stivarga (regorafenib) / Bayer, Tecentriq (atezolizumab) / Roche, zanzalintinib (XL092) / Exelixis
STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer (mCRC). (On Demand | Level 1, West Hall; Poster Board No. P9) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_929;
P3
In phase 1/2 trials, ICIs in combination with VEGFR2 multi-kinase inhibitors (MKIs) have demonstrated encouraging clinical activity in mCRC, including atezolizumab and durvalumab (ICIs) in combination with the MKI cabozantinib, with data suggesting a greater benefit in RAS wild-type (wt) vs mutant (mut) disease (Abrams TA, et al...Enrollment is ongoing. Clinical trial information: NCT05425940.
- | XL092 / Exelixis
Preclinical, Journal: Preclinical characterization of XL092, a novel receptor tyrosine kinase inhibitor of MET, VEGFR2, AXL, and MER. (Pubmed Central) - Nov 19, 2022
Additionally, XL092 promoted M2 to M1 repolarization of macrophages in vitro and inhibited primary human macrophage efferocytosis in a dose-dependent manner. In summary, XL092 was shown to have significant antitumor and immunomodulatory activity in animal models both alone and in combination with immune checkpoint inhibitors, supporting its evaluation in clinical trials.
- ||||| XL092 / Exelixis
Check out our TIP for STELLAR-002 exploring XL092 with immunotherapy combinations across solid tumors #SITC22 @DrChoueiri (Twitter) - Nov 11, 2022
- ||||| XL092 / Exelixis
Clinical, PK/PD data, Combination therapy: Open now: Dose-escalation+expansion study of safety+pharmacokinetics of XL092 as single agent+combination therapy in subjects with #inoperable locally advanced or metastatic solid tumors #kidneycancer @ExelixisInc @UMGCCC @NIH @NCIResearchCtr @apolo_andrea https://t.co/03ZW0IcXVY (Twitter) - Oct 28, 2022
- XL092 / Exelixis
A multicohort phase 1b study (STELLAR-002) of XL092 in combination with immunotherapy in patients with advanced solid tumors (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1059;
P1
Trial Registration Trial registry is ClinicalTrials.gov NCT05176483 Ethics Approval The study will adhere to the principles outlined in ”Guideline for Good Clinical Practice” (GCP) and remain consistent with the most recent version of the Declaration of Helsinki. Consent Patients will be required to provide written informed consent.
- || zanzalintinib (XL092) / Exelixis
Enrollment change, Combination therapy, Metastases: STELLAR-001: A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (clinicaltrials.gov) - Sep 22, 2022
P1, N=1195, Recruiting, Sponsor: Exelixis
Consent Patients will be required to provide written informed consent. N=800 --> 1195
- ||| Stivarga (regorafenib) / Bayer, Tecentriq (atezolizumab) / Roche, XL092 / Exelixis
🙏🏻 @pashtoonkasi .. glad the Camilla combo results supported development of the ongoing STELLAR 303 testing 2nd generation VEGFR2-MET TKI, XL092 plus Atezo vs regorafenib in 3rd line CRC. Results regardless of outcome will guide future trajectory of this & similar combo in CRC ✨ https://t.co/rBDhwKc4Al (Twitter) - Sep 18, 2022
- Tecentriq (atezolizumab) / Roche, XL092 / Exelixis
A phase I first-in-human study of XL092 in patients (pts) with locally advanced or metastatic solid tumors: Results from dose-escalation of XL092 alone and in combination with atezolizumab (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2421;
P1
PK, PD, and efficacy data support selection of a 100 mg dose for XL092 alone or with atezolizumab for further investigation. Expansion cohorts are ongoing in a number of tumor types.